Opthea Chances as a treament for Lymphangioleiomyomatosis

Just buying time and legal way to move shareholder equity into director equity ? Or is there something there there with LAM?

AI treatment.


-----------------

1) What drug are we talking about?

Opthea’s VEGF-C/VEGF-D blockade agent is sozinibercept (OPT-302). Mechanistically it’s a soluble VEGFR-3 “trap” fused to an IgG1 Fc domain, designed to bind and neutralize VEGF-C and VEGF-D, stopping them from activating VEGF receptors (VEGFR-2/VEGFR-3). In other words: it’s not anti-VEGF-A, it’s a ligand trap for the lymphangiogenic VEGFs.

There’s also older corporate history in oncology via Circadian / Ceres Oncology, which developed VGX-100, a selective anti-VEGF-C antibody, including combo with bevacizumab. Not identical (VEGF-C only vs VEGF-C + VEGF-D), but same general biological target neighborhood.

2) The two Phase 3 failures (wet AMD): what actually happened?

COAST (OPT-302 + aflibercept)

• Phase 3 wet AMD trial NCT04757636.

• Primary endpoint: change in BCVA (vision letters) baseline → Week 52.

• Population: treatment-naïve wet AMD; registry lists age ≥50, active CNV due to AMD, baseline BCVA range, etc.

• Result: failed. Combination arms basically matched (or slightly underperformed) aflibercept alone, with non-significant p-values in toplines.

• Safety: toplines describe combo as generally tolerable; no “we couldn’t dose it” narrative.

ShORe (OPT-302 + ranibizumab)

• Phase 3 wet AMD trial NCT04757610.

• Primary endpoint: change in BCVA baseline → Week 52.

• Result: failed. Opthea’s own toplines show the combo arms were numerically worse than ranibizumab alone by ~1–2 letters, with p-values not significant.

• After COAST + ShORe, Opthea/financing parties decided to discontinue wet AMD development.

This matters because two independent Phase 3 misses (with two different anti-VEGF-A backbones) is not “bad luck.” It’s usually a sign the biology isn’t moving the endpoint.

3) The earlier oncology program (Circadian / Ceres Oncology): what it was and why it stalled

Circadian’s oncology arm (Ceres Oncology) developed VGX-100, an anti-VEGF-C antibody, including cohorts in combo with bevacizumab.

In their 2014 release (ASCO-era data):

• 43 patients enrolled in Phase 1a/b dose escalation.

• Best response was mostly stable disease: 14/39 evaluable (36%), with durable SD ≥16 weeks in 5/39 (13%).

• Safety: common AEs included fatigue/rash/nausea/hypertension; a transient Grade 3 hypertension was described as a DLT.

No public “post-mortem,” but the overall vibe is classic Phase 1 oncology: tolerable, weak efficacy signal, no clear biomarker-defined responder population.

4) What do these failures imply? (in normal English)

Here’s the simplest read:

If you block VEGF-C/D in humans, the body often finds other ways around it — or VEGF-C/D simply isn’t the limiting factor that determines outcomes in complex disease. The wet AMD failures strongly support this idea, because the effect size wasn’t “small but promising.” It was essentially zero.

That doesn’t mean VEGF-C/D blockade is worthless everywhere. It does mean you need a very specific disease niche where the pathway is actually doing decisive work.

5) LAM biology: where VEGF-C/D might actually matter

LAM is tied to TSC1/2 dysfunction → mTOR activation, causing abnormal “LAM cells,” cystic lung destruction, and often lymphatic complications like chylous effusions and lymphatic masses.

A key point: VEGF-D is used clinically as a diagnostic biomarker and is associated with lymphatic involvement.
Also: mTOR inhibition (sirolimus) stabilizes lung function and lowers VEGF-D, with benefits that fade off treatment.

So: VEGF-D is definitely meaningful as a marker of a lymphatic phenotype. Whether it’s a true upstream “driver” of the core lung destruction is much less proven.

Translation: VEGF-C/D blockade might help the “lymphatic plumbing problems” of LAM, but it’s very unlikely to rebuild damaged lung architecture.

6) What’s a plausible “win” in LAM vs what’s basically fantasy?

Plausible targets (where biology matches mechanism):

• chylous effusions / chylothorax (less recurrence, less drainage)

• shrinkage of lymphatic masses (lymphangioleiomyomas)

• fewer procedures, better symptoms driven by lymphatic leak

Implausible targets:

• reversing established cystic lung destruction

• big FEV1 improvements in advanced cystic disease (beyond what sirolimus already does)

Cysts aren’t inflammation. They’re structural loss. VEGF-C/D blockade isn’t tissue regeneration.

7) My verdict (plain English, no corporate poetry)

This can be real science — but only in a narrow lane.

The credible lane is:
LAM patients with high VEGF-D and clinically significant lymphatic complications, where the trial aims to prove improved lymphatic outcomes (effusions, masses), not vague “LAM modification.”

If Opthea frames this as “treat the lymphatic phenotype of LAM,” I’d call it scientifically coherent with a plausible success envelope.

If they frame it as “broad LAM disease modifier” or imply major lung restoration, then based on two Phase 3 failures in another disease area, it starts looking like mostly narrative.

The biggest ways this can go wrong:

1. VEGF-D is a marker, not the cause (“smoke vs fire” problem).

2. Redundancy: the body routes around VEGF-C/D blockade (two Phase 3s hint this is common).

3. Biomarker mirage: if the drug binds VEGF-D, simple VEGF-D blood tests can look “better” due to assay interference rather than true biology.

4. Systemic dosing for LAM is not intravitreal dosing; exposure/safety dynamics change.

8) Quick timeline (anchored)

• 2014: Circadian/Ceres oncology reports VGX-100 Phase 1a/b: tolerable, mostly stable disease.

• FY2015: OPT-302 described as soluble VEGFR-3 targeting VEGF-C/-D escape biology.

• 2023: A randomized study reports BCVA benefit of OPT-302 combo vs ranibizumab (why Phase 3 was attempted).

• Mar 2025: COAST Phase 3 fails Week 52 BCVA.

• Mar 31 2025: ShORe Phase 3 fails; wet AMD program discontinued.

• Current: Opthea website discusses pivot/relaunch targeting LAM.

Final takeaway

LAM is one of the few places where VEGF-C/D blockade might have a rational niche — but it’s not the “cure LAM” story. It’s a “help lymphatic complications in a selected subgroup” story. The prior failures mean Opthea has to be extremely precise in population and endpoints, or this becomes a glossy rerun of the same biology that didn’t translate twice already.

If the LAM program is broad and endpointed on lung function without strong phenotype enrichment and clean PD strategy, then yeah: it smells more like runway than revelation.